logo
NHS told to help fat jab users keep weight off

NHS told to help fat jab users keep weight off

Telegraph2 days ago
The NHS has been told to help people taking weight-loss jabs keep the pounds off once they stop the drugs.
New guidance issued by the National Institute for Health and Care Excellence (Nice) said the health service should be helping people for at least one year after they stop the injections.
Health officials said many people regain weight after stopping treatment if they are not supported, and those coming off the fat jabs should be offered 'structured advice and follow-up support' to help prevent this.
An estimated 1.5 million people are taking weight-loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment.
It comes after the National Pharmacy Association warned that demand for the jabs was 'unsustainable' and could soon outstrip supply.
The new 'quality standard' from Nice says NHS patients should be monitored for at least a year after they complete treatment, and emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'.
This guidance for the NHS in England and Wales sets out expectations for health providers including how they should support patients.
Prof Jonathan Benger, the deputy chief executive and chief medical officer at Nice, said: 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme.
'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made.
'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 year plan to shift from a 'sickness service' to a genuine health service focused on prevention.'
The guidance says NHS services should monitor people for weight creeping back up and help implement 'if-then' plans so people know what steps to take if there is weight regain.
It also says they should work with the patients on making changes to their daily routines as well as eating and shopping habits.
Dr Rebecca Payne, the chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix.
'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits.
'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support.
'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term.
'This standard ensures healthcare services are equipped to provide that essential ongoing support.'
Prof Kamila Hawthorne, the chairman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk.
'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice.
'As a college, we've been clear that whilst weight-loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
An NHS spokesman said: 'While these new treatments are excellent at supporting weight loss, they're not a magic bullet and must be paired with wraparound support including advice on healthier diets and physical activity to see sustainable results, so we welcome new guidance on this for local services.
'The NHS is already supporting hundreds of thousands of people to lose weight through our 12-week digital weight management programme, and we are expanding this to 125,000 more people per year, so doubling the number of people who can access it, as part of the 10 year health plan.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This new SPF from ESPA hydrates, protects and leaves skin naturally radiant with 92% of users agreeing
This new SPF from ESPA hydrates, protects and leaves skin naturally radiant with 92% of users agreeing

The Independent

time14 minutes ago

  • The Independent

This new SPF from ESPA hydrates, protects and leaves skin naturally radiant with 92% of users agreeing

There's something quietly reassuring about a solid skincare routine, especially when it doesn't require a dozen complicated steps or leave you feeling slick. Still, for many of us SPF is the step that gets forgotten, skipped or reserved for holidays abroad. And who can blame us? Traditional sunscreens can feel chalky, greasy or leave behind a ghostly, stubborn white cast. The thing is: protecting your skin isn't just about beach days. With UV rays, blue light from screens and urban pollution all contributing to premature ageing, SPF really is an everyday essential – whether you're sitting on a sun-drenched patio or just replying to emails indoors. Enter ESPA's new Protect & Brighten Daily Skin Shield SPF 50 (£40, Designed to slot seamlessly into your morning routine, it promises comfortable and lightweight protection, and leaves your skin with a natural luminosity that looks fresh, not filtered. In fact, 92 per cent of users said it gave their skin a visible dewy glow. For those concerned about signs of ageing, or simply wanting to maintain a youthful-looking complexion, this may well be the SPF you've been searching for. So, what makes it stand out in a sea of sun protection? And what's behind these glow-giving claims? Let's take a look. More than sun care Unlike heavy-duty sunscreen sprays that sit on top of the skin, ESPA's Skin Shield is formulated like a luxurious moisturiser that just so happens to include SPF 50. It's powered by hydrating hyaluronic acid, antioxidant-rich beta carotene and Chinese butterfly bush extract, which help to defend against UV rays, blue light and pollution. Together, they offer more than just sun protection: they soothe, hydrate and actively help to reduce the visible signs of ageing. From fine lines to sun spots and uneven tone, the daily aggressors this product guards against are relevant year-round – not just during a heatwave. And because the texture is so lightweight and non-greasy, it layers easily over your existing moisturiser or under make-up (if you're wearing any), without pilling or feeling cakey. A 3-in-1 primer, protector and glow-booster The real beauty of ESPA's Skin Shield lies in its finish. Fast-absorbing and silky, it gives skin a subtle radiance that leaves you looking lit-from-within, naturally and without the strobe effect of a highlighter or shimmer. There's no white cast, no stickiness or even the sensation that you're wearing anything. It's the kind of multi-tasker we look to in the summer months: simplifying your morning routine but sacrificing neither sun protection nor skin smoothing. You can use it as your final skincare step, a smoothing primer or the one thing you slap on if you're running out the door. According to user trials, 96 per cent agreed their skin looked brighter after just two weeks of use and 83 per cent said fine lines and wrinkles appeared softened. For a no-makeup-makeup look, this one's doing the heavy lifting. For all skin types and every kind of day One of the biggest pain points with SPF is inclusivity, and ESPA has paid attention here. Skin Shield is wearable on all tones and textures, from dry and sensitive to oily or blemish-prone. It doesn't clog, flake or fight your base, and it's as comfortable for long hikes as it is for commuting. Add in the fact that you're getting broad-spectrum UVA/UVB coverage and oxidative stress protection in one simple step, and it starts to feel less like a luxury and more like a non-negotiable. Plus, with 20 per cent off (was £50, now £40, it's a timely excuse to elevate your skincare essentials before the seasons shift.

Researchers find milk type that increases risk of heart disease and death
Researchers find milk type that increases risk of heart disease and death

The Independent

time14 minutes ago

  • The Independent

Researchers find milk type that increases risk of heart disease and death

A 33-year study conducted in Norway has investigated the long-term health impacts of consuming full-fat versus low-fat milk. Researchers analysed health data from 73,860 individuals, finding that the fat content of milk influenced the risk of death from heart disease. The study revealed that individuals who consumed full-fat milk had a higher mortality risk compared to those who drank low-fat milk. Specifically, consuming low-fat milk was linked to an 11 per cent lower overall mortality risk and a 7 per cent reduced risk of cardiovascular disease compared to whole milk. These findings support current NHS health advice, which cautions against high intake of saturated fat found in full-fat dairy due to its link to increased cholesterol and heart disease risk.

Daily weight loss pill helps patients lose 12% of body weight
Daily weight loss pill helps patients lose 12% of body weight

BBC News

time15 minutes ago

  • BBC News

Daily weight loss pill helps patients lose 12% of body weight

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The manufacturer, Eli Lilly, says the drug, which is not yet licensed, could be available next daily pill, called orforglipron, works by suppressing appetite and making you feel more results of a major trial show those on the highest dose lost an average of 12 kilos (nearly two stone) over 16 months but about one in 10 stopped taking the pills due to side effects, including nausea and vomiting. In addition to weight loss, participants also benefited from reductions in cholesterol, blood fats and blood Kenneth Custer of Eli Lilly said the company was planning to submit the drug for licensing before the end of the year and preparing for a "global launch to address this urgent pubic health need".So where might this weight loss pill fit in to the blockbuster multi-billion pound market dominated by injectable drugs like Mounjaro, Wegovy and Ozempic?The pill is much less effective than 12% weight loss achieved by those taking orforglipron compares to 22% weight loss for patients on Mounjaro, given by weekly injection. Both drugs are made by Eli Lilly. Despite being less effective, there is likely to be a significant market for weight loss pills, as a needle-free means of cutting obesity experts hope the oral drug will be far cheaper than current injectables which would make it available to many more patients. The full results of the trial will be presented next month at the European Association for the Study of Diabetes annual meeting and published in a peer-reviewed manufacturer, Novo Nordisk, also has an oral version of its injectable drug Wegovy which it has already submitted for approval in the trials, patients on the highest dose of the Novo Nordisk daily pill lost around 15% of their bodyweight after 64 weeks.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store